Felix Nguyen

Felix Nguyen

Auto-generated profile, based on publicly available information

Felix Nguyen

Center for Structural Heart Disease, Henry Ford Health System, Detroit, MI (J.X.F., P.A.V., T.M.F., L.K.L.L., J.C.L., P.E.G., B.Z., H.A., G.K.F., F.N., T.A., O.A., G.R., W.W.O.N., B.P.O.N.).

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2024 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
KGKartik Gupta
Kartik Gupta
VJVardhmaan Jain
Vardhmaan Jain
TKTanya Singh Kakar
Tanya Singh Kakar
FNFelix Nguyen
Felix Nguyen
GRGautam Rangavajla
Gautam Rangavajla
MLMarc Lahiri
Marc Lahiri

18 December 2024 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
GGGennaro Giustino
Gennaro Giustino
JFJonathan Xinguo Fang
Jonathan Xinguo Fang
TFTiberio M. Frisoli
Tiberio M. Frisoli
JLJames C. Lee
James C. Lee
FNFelix Nguyen
Felix Nguyen
BOBrian P. O’NEill
Brian P. O’NEill

1 December 2021 in The American Journal of Cardiology
Verified
Journal Article
Closed access
FNFelix D. Nguyen
Felix D. Nguyen
MRMario Rodriguez
Mario Rodriguez
CKChayakrit Krittanawong
Chayakrit Krittanawong
RWRonald Witteles
Ronald Witteles
DLDaniel J. Lenihan
Daniel J. Lenihan

1 October 2025 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
JFJonathan Xinguo Fang
Jonathan Xinguo Fang
PVPedro A. Villablanca
Pedro A. Villablanca
TFTiberio Frisoli
Tiberio Frisoli
GGGennaro Giustino
Gennaro Giustino
LLLeo Kar Lok Lai
Leo Kar Lok Lai
BOBrian P. O’NEill
Brian P. O’NEill
BACKGROUND: The Evoque system is the first commercially available transcatheter tricuspid valve replacement (TTVR) system in the United States. However, challenging anatomy in real-world patients could preclude successful transfemoral Evoque TTVR. We aim to investigate the feasibility of the transjugular Evoque TTVR in anatomy unsuitable for a transfemoral approach. METHODS: Eleven patients with challenging anatomy underwent transjugular Evoque TTVR at a high-volume center in the United States from February 2024 to January 2025, following an unsuccessful transfemoral attempt (n=9) or anatomic unsuitability (n=2). Procedural characteristics, intraprocedural success, periprocedural outcomes, echocardiographic findings, and 30-day clinical outcomes were assessed using the Tricuspid Valve Academic Research Consortium definitions. The procedural technique is provided in the accompanying supplement. RESULTS: Intraprocedural success was achieved in all 11 patients, with reasonable procedural time and no major procedural complications, except for 1 pacemaker implantation. At 30 days, the clinical success rate was 100%. Tricuspid regurgitation was reduced to none-to-trivial in 8 patients, mild in 2 patients, and moderate in 1 patient. There was no stroke, mortality, or rehospitalization. Nine out of 11 patients experienced an improvement in New York Heart Association functional class. CONCLUSIONS: In the largest single-center cohort of patients reported to date, transjugular Evoque TTVR demonstrated favorable intraprocedural, periprocedural, and short-term clinical outcomes, and was found to be a feasible alternative for patients with anatomy unsuitable for transfemoral Evoque TTVR.

16 July 2025 in Structural Heart
Verified
Journal Article
Open access
GRGautam Rangavajla
Gautam Rangavajla
RPRitik Patel
Ritik Patel
FNFelix Nguyen
Felix Nguyen
BVBrian Vickers
Brian Vickers
OAOmar Abdelhai
Omar Abdelhai
TFTiberio Frisoli
Tiberio Frisoli
• Based on a real-world study of 106 Evoque transcatheter tricuspid valve replacement (TTVR) recipients, a total of 14 (25%) cases of new atrioventricular (AV) block occurred after Evoque implantation in the 55 patients without prior pacemakers who met study inclusion criteria. This incidence is similar to that reported in the TRISCEND II clinical trial. • New AV block occurred in a median of 26 hours after Evoque TTVR (interquartile range: 5-60 hours), but there were cases of new AV block that occurred as late as 7 days after the procedure. • Of the 14 new cases of AV block, 12 were treated successfully with implantation of a leadless pacemaker (Micra) under fluoroscopic guidance without procedural complications or compromising the valve implantation. • The institutional strategy of 48-hour post-Evoque inpatient monitoring for all patients followed by mobile cardiac outpatient telemetry identified 11 of 14 cases of new AV block as before discharge from the hospital and 1 case as an outpatient before symptom onset.

8 August 2025 in medRxiv
Verified
Preprint
Open access
PDF file
RFRaef Fadel
Raef Fadel
JMJoseph B Miller
Joseph B Miller
BCBernard Cook
Bernard Cook
FNFelix Nguyen
Felix Nguyen
MAMohammad Alqarqaz
Mohammad Alqarqaz
JMJames McCord
James McCord
Background: Unstable angina has become an exceedingly rare diagnosis in the era of high-sensitivity cardiac troponin (hs-cTn). We sought to identify the incidence of unstable angina and characterize patients with low hs-cTn in Emergency Departments (EDs). Methods: A prespecified secondary analysis of the R apid A cute C oronary Syndrome E xclusion using high-sensitivity I cardiac T roponin (RACE-IT) trial was conducted. RACE-IT was a stepped-wedge randomized trial comparing two rule-out protocols (0/1- and 0/3-hour) for myocardial infarction (MI) in nine EDs from July 2020 to April 2021. All patients had hs-cTnI (Beckman Coulter) concentrations below or equal to the 99 th percentile upper reference limit of 18 ng/L. The primary outcome was unstable angina, based on the ISCHEMIA trial definition, which required electrocardiographic changes or findings at coronary angiography (angiographic evidence of plaque rupture or thrombus). Results: Of the 32,608 patients in the trial, 60 patients (0.2%) met the definition of unstable angina of which 46 (77%) had obstructive disease at coronary angiography and 17 (28%) had an ischemic electrocardiogram. Coronary revascularization was performed in 45 (75%) patients and 7 (12%) had left main or 3-vessel coronary artery disease. There were 7 (12%) patients with non-obstructive coronary artery disease, and 7 (12%) who had angiographically unremarkable coronary arteries. Patients with unstable angina were older (p=0.032), more likely to be male (p=0.012), with a higher prevalence of hypertension (p<0.001), known coronary artery disease (p<0.001), peripheral vascular disease (p=0.030), and a higher serum creatinine (p=0.043). At 30 days, two patients had a type 1 MI and there were no deaths. Conclusion: Unstable angina was diagnosed in 1 in 500 patients with a low hs-cTnI value at presentation to the ED and these patients have an excellent prognosis at 30 days. These patients tend to not have high-risk anatomy and 1 in 4 have non-obstructive coronary artery disease or angiographically unremarkable coronary arteries.